1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Why Your ISTA Shares Sold as Low as They Did

Discussion in 'Ista Pharma' started by OCI, May 25, 2013 at 4:51 PM.

Tags: Add Tags
  1. OCI

    OCI Guest

    All you ISTA shareholders who thought B&L bought you out too cheaply - here's why:


    B&L knew they were going to have to plead you out to felony charges for the misconduct of your previous management. That reduced their offering price. That reduced the amount you got for each share. In total, some $33 million.

    You need the thank your previous management for your losses. Or hold them accountable. Your decision.
  2. Anonymous

    Anonymous Guest

    OK, somebody get Vince on the phone stat! He's either on his yacht or plane.

    I'm steaming mad!!!
  3. Anonymous

    Anonymous Guest

    Yep! KKN one of your infamous managers knew all about this. Can you say dirty manager?!
    That's one of many reasons why B&L fired her.